Pailin Biotech: Announcement on abnormal fluctuations in stock trading
Securities code: 000403 Securities abbreviation: Pais Shuanglin Biotech Announcement number: 2026-040 Pais Shuanglin Biopharmaceutical Co., Ltd.
Announcement on abnormal stock trading fluctuations
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
1. Abnormal fluctuations in stock trading
The cumulative decline in the closing price of the shares of Pais Shuanglin Biopharmaceutical Co., Ltd. (hereinafter referred to as the "Company") for three consecutive trading days (June 17, 2026, June 18, 2026, and June 22, 2026) exceeded 20%. According to the relevant regulations of the Shenzhen Stock Exchange, it is an abnormal fluctuation in stock trading.
2. Situations that the company pays attention to and verifies
In response to the abnormal fluctuations in the company's stock trading, the company has verified the relevant matters and inquired the company's controlling shareholders. The relevant situation is now explained as follows:
There is no need to correct or supplement the information previously disclosed by the company.
Except for the major events of the "Announcement on the Termination of the Transfer of Control" (Announcement No.: 2026-039) disclosed by the company on June 18, 2026, no other undisclosed major information reported by the public media recently that may or has had a greater impact on the company's stock trading price has been found.
The company's recent production and operation conditions have been normal, there have been no major changes in the internal and external operating environment, and all operations and management work have been carried out in an orderly manner.
After verification, except for the major matters in the "Announcement on the Termination of the Transfer of Control" (Announcement No.: 2026-039) disclosed by the company on June 18, 2026, the company, the controlling shareholder, its persons acting in concert, and the actual controller have no other major matters about the company that should be disclosed but have not been disclosed, and there are no major matters in the planning stage.
After verification, the controlling shareholder, its persons acting in concert, and the actual controller did not buy or sell the company's stocks during the period of abnormal stock trading fluctuations.
3. Whether there is an explanation of information that should be disclosed but has not been disclosed
The company's board of directors confirms that, in addition to the aforementioned matters, the company currently does not have any undisclosed matters that should be disclosed in accordance with the "Shenzhen Stock Exchange Stock Listing Rules" or any planning, negotiations, intentions, agreements, etc. related to the matter; the board of directors is also not informed that the company has undisclosed information that should be disclosed in accordance with the "Shenzhen Stock Exchange Stock Listing Rules" and has a greater impact on the trading price of the company's stocks and its derivatives; there is no need to correct or supplement the information previously disclosed by the company.
4. Risk warning
The company does not violate fair information disclosure.
The company's 2025 annual report and 2026 first quarter report have been disclosed on schedule on April 29, 2026.
The company solemnly reminds investors: "Securities Times", "Shanghai Securities News" and Juchao Information Network (http://www.cninfo.com.cn/) are the company's designated information disclosure media. All the company's information is subject to the information published in the above designated media. Investors are kindly requested to invest rationally and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Pais Shuanglin Biopharmaceutical Co., Ltd.
June 23, 2026